We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Czech Republic's drug regulator, SUKL, has indicated that price
rises in the country are soaring as the country's market increasingly integrates
with the European Union (EU).
India's government has pledged to adopt any necessary measures to
improve public access to medicines, but officials admit that the country lacks
a world-class regulatory system to ensure this adoption.
UK drugmaker ProStrakan said it had raised 40 million pounds ($73 million) in
a placing at 100 pence per share, valuing the company at around 180 million
pounds, down sharply from the valuation it had hoped to achieve a month ago.
Clemex Technologies announces that its Board of Directors approved the redemption
of half of the $500,000 debentures held by 3880095 Canada (Raffaele Gerbasi),
at its Board meeting.
Two San Diego-based specialty pharmaceutical firms, Verus Pharmaceuticals Inc.
and Somaxon Pharmaceuticals Inc., announced they raised $163 million total in
venture capital funding.
InfaCare Pharmaceutical Corporation and Recordati, a pharmaceutical company
based in Milan, Italy, jointly announced the signing of an exclusive licensing
agreement that provides Recordati the rights to develop and market Stanate (stannsoporfin),
a first-in-class agent for the treatment of jaundice in babies, for Europe and
for certain territories of Northern Africa and the Middle East.
Germany's Schering AG (SHR)
Monday opened its Asia-Pacific headquarters in Singapore, joining a number of
drug companies that have decided to locate their regional management activities
in the city-state.
Israel is likely to ignore US opposition to two key new intellectual
property measures: the data exclusivity bill approved in March and a draft amendment
to the country's Patent Law.
Influential media sources have urged Brazil's president, Luiz Inacio 'Lula'
da Silva, to veto a law that envisages breaking patents held by US drugmakers
on HIV/AIDS therapies.